These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 23208836)

  • 1. Antiangiogenic therapy for cancer: an update.
    Al-Husein B; Abdalla M; Trepte M; Deremer DL; Somanath PR
    Pharmacotherapy; 2012 Dec; 32(12):1095-111. PubMed ID: 23208836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.
    Girard N
    Expert Rev Anticancer Ther; 2013 Oct; 13(10):1193-206. PubMed ID: 24134421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent concepts of antiangiogenic therapy.
    Konno H; Yamamoto M; Ohta M
    Surg Today; 2010 Jun; 40(6):494-500. PubMed ID: 20496129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab (Avastin).
    Mukherji SK
    AJNR Am J Neuroradiol; 2010 Feb; 31(2):235-6. PubMed ID: 20037132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic therapy: a novel approach to overcome tumor hypoxia.
    Peng F; Chen M
    Chin J Cancer; 2010 Aug; 29(8):715-20. PubMed ID: 20663317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor angiogenesis revisited: Regulators and clinical implications.
    Ronca R; Benkheil M; Mitola S; Struyf S; Liekens S
    Med Res Rev; 2017 Nov; 37(6):1231-1274. PubMed ID: 28643862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond bevacizumab: antiangiogenic agents.
    Rogosin S; Sandler AB
    Clin Lung Cancer; 2012 Sep; 13(5):326-33. PubMed ID: 22297207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.
    Lindholm EM; Kristian A; Nalwoga H; Krüger K; Nygård S; Akslen LA; Mælandsmo GM; Engebraaten O
    Mol Oncol; 2012 Aug; 6(4):418-27. PubMed ID: 22521242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization.
    Weiss A; van Beijnum JR; Bonvin D; Jichlinski P; Dyson PJ; Griffioen AW; Nowak-Sliwinska P
    J Cell Mol Med; 2014 Mar; 18(3):480-91. PubMed ID: 24450440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic agents: fueling cancer's hypoxic roots.
    Conley SJ; Wicha MS
    Cell Cycle; 2012 Apr; 11(7):1265-6. PubMed ID: 22421155
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
    Teoh D; Secord AA
    Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab antiangiogenic therapy for glioblastoma.
    Junck L
    Neurology; 2011 Feb; 76(5):414-5. PubMed ID: 21282587
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
    Quesada AR; Medina MA; Alba E
    Bioessays; 2007 Nov; 29(11):1159-68. PubMed ID: 17935210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
    Sessa C; Guibal A; Del Conte G; Rüegg C
    Nat Clin Pract Oncol; 2008 Jul; 5(7):378-91. PubMed ID: 18560389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic strategies and agents in clinical trials.
    Rosen L
    Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of angiogenesis in cancers.
    Pang RW; Poon RT
    Vasc Health Risk Manag; 2006; 2(2):97-108. PubMed ID: 17319453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.